This cluster is a non-event for the stock — option exercises and subsequent sales by C-suite insiders are routine post-vesting liquidity events. Monitor upcoming pipeline catalysts (Week 28 EVERLAST-A data end-Q3 2026, ORKA-001 Phase 3 start 1H 2027) for actual equity-moving information.
Price Chart
Executive Summary
Two senior insiders at Oruka Therapeutics (CMO and General Counsel) executed large-derivative exercises and sold shares on the open market for a total of $653K in net sales in the week following Q2 2026 earnings. The sales follow option exercises, not direct bearish conviction, and represent ~0.009% of the $7.4B market cap — well below materiality thresholds. The insider cluster is a routine post-vesting pattern, not a predictive signal.
Key Financial Metrics
Key Facts
- CMO Goncalves sold ~7,000 shares for ~$784K; General Counsel Quinlan sold ~52,000 shares for ~$5.6M — both after exercising options at $0–$12.50 strike prices.
- Total open-market sales of ~$653K represent ~0.009% of Oruka's $7.4B market cap — trivial.
- Insider activity occurred 7 days after Q2 2026 earnings (consensus-beating EPS loss of $0.55 vs $0.49) following an upsized $700M April 2026 public offering; no material negative catalyst.
- Historical calibration for this filing type shows score-2 neutral reports on ORKA have had strong positive T+20 performance (+30.20% average alpha), but this is backward-looking and not predictive for the current filing.
Financial Impact
~$6.4M in aggregate insider sales (including option exercises), but open-market net sales of $653K — immaterial relative to $7.4B market cap and $1.1B cash balance.
Risk Factors
- Insider sales could pick up in volume or frequency ahead of clinical readouts, signaling reduced conviction.
- Pre-commercial biotech's sole catalyst is pipeline data — any negative readout would be highly material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1787004617759 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access